← All trials
NCT06049147
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2021
- Primary completion
- Aug 24, 2023
- Completion date
- Aug 24, 2023
- First posted
- Sep 21, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 72
- Arms / groups
- 11 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medibiofarma S.L.Lead sponsor
- University of BarcelonaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.